ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is SAGE Therapeutics, Inc. ?
1
With a growth in Net Sales of 125.13%, the company declared Very Positive results in Jun 25
- OPERATING CASH FLOW(Y) Highest at USD -289.34 MM
- NET SALES(Q) Highest at USD 31.66 MM
- OPERATING PROFIT(Q) Highest at USD -54.09 MM
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to SAGE Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is SAGE Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
SAGE Therapeutics, Inc.
-11.07%
-0.27
74.15%
S&P 500
13.22%
0.90
19.99%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
51.20%
EBIT Growth (5y)
8.43%
EBIT to Interest (avg)
-255.13
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
2,007.88%
ROE (avg)
6.64%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.05
EV to EBIT
-0.02
EV to EBITDA
-0.02
EV to Capital Employed
-0.57
EV to Sales
0.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-81.01%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -289.34 MM
NET SALES(Q)
Highest at USD 31.66 MM
OPERATING PROFIT(Q)
Highest at USD -54.09 MM
OPERATING PROFIT MARGIN(Q)
Highest at -170.86 %
NET PROFIT(Q)
Highest at USD -49.88 MM
RAW MATERIAL COST(Y)
Fallen by -19.47% (YoY
PRE-TAX PROFIT(Q)
At USD -49.88 MM has Grown at 39.91%
EPS(Q)
Highest at USD -0.79
-7What is not working for the Company
NET SALES(9M)
At USD 58.54 MM has Grown at -38.07%
CASH AND EQV(HY)
Lowest at USD 789.43 MM
Here's what is working for SAGE Therapeutics, Inc.
Net Sales
At USD 31.66 MM has Grown at 167.15%
over average net sales of the previous four periods of USD 11.85 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -289.34 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 31.66 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit
Highest at USD -54.09 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -170.86 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD -49.88 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -49.88 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Pre-Tax Profit
At USD -49.88 MM has Grown at 39.91%
over average net sales of the previous four periods of USD -83.01 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -49.88 MM has Grown at 39.91%
over average net sales of the previous four periods of USD -83.01 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.79
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -19.47% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for SAGE Therapeutics, Inc.
Cash and Eqv
Lowest at USD 789.43 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
